Mechanisms of IVIG action in immune thrombocytopenic purpura

Clinical Laboratory

Volumn 50, Issue 3-4, 2004, Pages 133-140

  Hansen, Ryan J ^a,b   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Autoimmune diseases; Immune thrombocytopenia; Intravenous immune globulin; IVIG

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CORTICOSTEROID; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN G; THROMBOCYTE ANTIBODY;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; DRUG COST; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HYPOTHESIS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEDICAL RESEARCH; NONHUMAN; PHAGOCYTOSIS; REVIEW; THROMBOCYTE;

ANIMALS; AUTOANTIBODIES; BLOOD PLATELETS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

PURPURA;

EID: 1842737035     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3
2. Harrington W, Minnich V, Hollingsworth J, Moore C. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38: 1
3. Shulman N, Marder V, Weinrach R. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Ann NY Acad Sci 1965; 124: 499
4. van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982; 59: 23
5. Woods VL, Jr., Kurata Y, Montgomery RR, et al. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood 1984; 64: 156
6. Fujisawa K, Tani P, McMillan R. Platelet-associated antibody to glycoprotein IIb/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cation-dependent antigens. Blood 1993; 81: 1284
7. Hou M, Stockelberg D, Kutti J, Wadenvik H. Immunoglobulins targeting both GPIIb/IIIa and GPIb/IX in chronic idiopathic thrombocytopenic purpura (ITP): evidence for at least two different IgG antibodies. Br J Haematol 1997; 98: 64
8. Blanchette V, Freedman J, Garvey B. Management of chronic immune thrombocytopenic purpura in children and adults. Semin Hematol 1998; 35: 36
9. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228
10. Bussel JB, Hilgartner MW. Intravenous immunoglobulin therapy of idiopathic thrombocytopenic purpura in childhood and adolescence. Hematol Oncol Clin North Am 1987; 1: 465
11. Simpson KN, Coughlin CM, Eron J, Bussel JB. Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. Semin Hematol 1998; 35: 58
12. Freedman J, Blanchette M. Idiopathic thrombocytopenic purpura (ITP): a historical odyssey. Acta Paediatr Suppl 1998; 424: 3
13. Blanchette VS, Kirby MA, Turner C. Role of intravenous immunoglobulin G in autoimmune hematologic disorders. Semin Hematol 1992; 29: 72
14. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306: 1254
15. Tsubakio T, Kurata Y, Katagiri S, et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 1983; 53: 697
16. Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of auto-antibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989; 74: 2414
17. Mehta YS, Badakere SS. In-vitro inhibition of antiplatelet auto-antibodies by intravenous immunoglobulins and Rh immunoglobulins. J Postgrad Med 1996; 42: 46
18. Basta M, Langlois PF, Marques M, Frank MM, Fries LF. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989; 74: 326
19. Grossi A, Vannucchi AM, Casprini P, Morfini M, Ferrini PR. Effects of high-dose intravenous gammaglobulin on kinetic parameters of 51Cr-labelled platelets in chronic ITP. Haematologica 1986; 71: 123
20. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484
21. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and anti-platelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002; 100: 208
22. Hansen RJ, Balthasar JP. PK/PD modeling of the effects of intravenous immunoglobulin on the disposition of anti-platelet antibodies in a rat model of immune thrombocytopenia. Journal of Pharmaceutical Sciences 2003; 92: 1206
23. Uchida T, Yui T, Umezu H, Kariyone S. Prolongation of platelet survival in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. Thromb Haemost 1984; 51: 65
24. Schmidt RE, Budde U, Broschen-Zywietz C, Schafer G, Mueller-Eckhardt C. High dose gammaglobulin therapy in adults with idiopathic thrombocytopenic purpura (ITP). Clinical effects. Blut 1984; 48: 19
25. Schmidt KG, Rasmussen JW, Diederichsen H, Ulrich M. Release of platelets into the circulation induced by gamma globulin treatment in a case of idiopathic thrombocytopenic purpura. Blut 1984; 48: 27
26. Budde U, Harbrecht U. Platelet kinetics after high dose intravenous gamma globulin. Thrombosis and Haemostasis 1984; 51: 412
27. Morfini M, Vannucchi AM, Grossi A, Cinotti S, Rafanelli D, Ferrini PR. Direct evidence that high dose intravenous gammaglobulin blocks splenic and hepatic sequestration of 51Cr-labeled platelets in ITP. Thrombosis and Haemostasis 1985; 54: 554
28. Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999; 93: 1951
29. Bussel JB, Kimberly RP, Inman RD, et al. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983: 62: 480
30. Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 1984; 132: 745
31. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1995; 3: 21
32. Debre M, Bonnet MC, Fridman WH, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342: 945
33. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986; 314: 1236
34. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 2: 193
35. Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)]. Blut 1984: 49: 29
36. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001: 98: 1095
37. Newland AC, Macey MG, Veys PA. Cellular changes during the infusion of high dose intravenous immunoglobulin. Blut 1989; 59: 82
38. Tovo PA, Miniero R, Fiandino G, Saracco P, Messina M. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr 1984; 105: 676
39. Bussel J, Pahwa S, Porges A, et al. Correlation of in vitro antibody synthesis with the outcome of intravenous gamma-globulin treatment of chronic idiopathic thrombocytopenic purpura. J Clin Immunol 1986; 6: 50
40. Dammacco F, Iodice G, Campobasso N. Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro. Br J Haematol 1986; 62: 125
41. Bordet JC, Follea G, Carosella E, Dechavanne M. Intravenous high-dose IgG therapy induced alterations of spleen lymphocyte IgM secretion and T cell subsets in patients with idiopathic thrombocytopenic purpura. Thromb Res 1987; 47: 165
42. Winiarski J, Elinder G. Immunological effects of intravenous gammaglobulin treatment in childhood idiopathic thrombocytopenic purpura. Scand J Haematol 1986; 37: 175
43. Delfraissy JF, Tchernia G, Laurian Y, Wallon C, Gallanaud P, Dormont J. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol 1985; 60: 315
44. Engelhard D, Waner JL, Kapoor N, Good RA. Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr 1986; 108: 77
45. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990; 71: 372
46. Andersson UG, Bjork L, Skansen-Saphir U, Andersson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211
47. Andersson U, Bjork L, Skansen-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139: 21
48. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993; 92: 2533
49. Svenson M, Hansen MB, Ross C, et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998; 91: 2054
50. Prasad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161: 3781
51. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765
52. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001; 115: 679
53. Hansen RJ, Balthasar JP. IVIG effects on antiplatelet antibody levels and on platelet opsonization in ITP. Blood 2003; 101: 1659
54. Hed J. Role of complement in immune or idiopathic thrombocytopenic purpura. Acta Paediatr Suppl 1998; 424: 37
55. Hauch TW, Rosse WF. Platelet-bound complement (C3) in immune thrombocytopenia. Blood 1977; 50: 1129
56. McMillan R, Martin M. Fixation of C3 to platelets in vitro by antiplatelet antibody from patients with immune thrombocytopenic purpura. Br J Haematol 1981; 47: 251
57. Tsubakio T, Tani P, Curd JG, McMillan R. Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol 1986; 63: 293
58. Winiarski J, Kreuger A, Ejderhamn J, Holm G. High dose intravenous IgG reduces platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura. Scand J Haematol 1983; 31: 342
59. Berger M, Rosenkranz P, Brown CY. Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clin Immunol Immunopathol 1985; 34: 227
60. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in itro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991: 77: 376
61. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84: 1974
62. Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001; 124: 282
63. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6: 683
64. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227
65. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996; 26: 690
66. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 1996; 93: 5512
67. Brambell F, Hemmings W, Morris I. A theoretical model of gamma-globulin catabolism. Nature 1964; 203: 1352
68. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thrombosis and Haemostasis 2002; 88: 898
69. Kelton JG. The mechanism of action of high-dose IgG in idiopathic thrombocytopenic purpura. Blood 2002; 100: 1933
70. Bussel JB. Another interaction of the FcR system with IVIG. Thrombosis and Haemostasis 2002; 88: 890